{"schema_version":"secwatch.filing_event.v1","accession":"0001110803-25-000071","form_type":"8-K","ticker":"ILMN","cik":"0001110803","company_name":"ILLUMINA, INC.","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.816144+00:00","generated_at":"2026-05-17T01:14:12.271490+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Illumina Q3 revenue $1.08B flat YoY, non-GAAP EPS $1.34 beats; raises FY EPS guidance to $4.65-$4.75","bullets":["Q3 GAAP diluted EPS $0.98, non-GAAP diluted EPS $1.34; non-GAAP operating margin 24.5%.","Revenue $1.08B flat YoY on reported and constant currency; returned to growth ex-China.","FY2025 guidance raised: revenue decline narrowed to (1.5%)-(0.5%), non-GAAP EPS to $4.65-$4.75 from $4.45-$4.55.","Repurchased 1.2M shares for $120M at avg $97.10; cash flow from ops $284M, free cash flow $253M.","Launched new products: 5-base solution, Constellation mapped read tech, BioInsight, and Illumina Protein Prep."],"urls":{"canonical":"https://secwatch.observer/filing/0001110803-25-000071","json":"https://secwatch.observer/filing/0001110803-25-000071.json","markdown":"https://secwatch.observer/filing/0001110803-25-000071.md","text":"https://secwatch.observer/filing/0001110803-25-000071.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1110803/000111080325000071/0001110803-25-000071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1110803/000111080325000071/ilmn-20251030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:14:12.271490+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}